Mural Oncology plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MURA research report →
About the company
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12.
- CEO
- Caroline J. Loew
- IPO
- 2023
- Employees
- 116
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $35.38M
- P/E
- -0.29
- P/S
- 0.00
- P/B
- 0.64
- EV/EBITDA
- 0.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -131.47%
- ROIC
- -179.73%
- Revenue
- $0 · 0.00%
- Net Income
- $-128,514,000 · 38.05%
- EPS
- $-7.58 · 39.02%
- Op Income
- $-138,262,000
- FCF YoY
- 34.93%
- 52W High
- $4.74
- 52W Low
- $0.95
- 50D MA
- $2.08
- 200D MA
- $2.37
- Beta
- 2.96
- Avg Volume
- 170.82K
Get TickerSpark's AI analysis on MURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 5, 25 | Hickey Benjamin | sell | 15,021 |
| Dec 5, 25 | Hickey Benjamin | sell | 8,637 |
| Dec 5, 25 | Hickey Benjamin | sell | 8,462 |
| Dec 5, 25 | Loew Caroline | sell | 293,059 |
| Dec 5, 25 | Loew Caroline | sell | 379,690 |
| Dec 5, 25 | Loew Caroline | sell | 134,225 |
| Dec 5, 25 | Loew Caroline | sell | 90,025 |
| Dec 5, 25 | Cuss Francis M | sell | 8,637 |
| Dec 5, 25 | Cuss Francis M | sell | 8,462 |
| Dec 5, 25 | Cuss Francis M | sell | 15,021 |
Our MURA coverage
Recent articles, reports, and earnings notes.
No research on MURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MURA report →Similar companies
Peers in the same neighborhood.